Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges.

Lehmann-Horn K, Kronsbein HC, Weber MS.

Ther Adv Neurol Disord. 2013 May;6(3):161-73. doi: 10.1177/1756285612474333.

2.

Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.

Lehmann-Horn K, Kinzel S, Weber MS.

Int J Mol Sci. 2017 Sep 23;18(10). pii: E2048. doi: 10.3390/ijms18102048. Review.

3.

B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.

Kinzel S, Weber MS.

CNS Drugs. 2016 Dec;30(12):1137-1148. Review.

PMID:
27844213
4.

Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders.

Lehmann-Horn K, Schleich E, Hertzenberg D, Hapfelmeier A, Kümpfel T, von Bubnoff N, Hohlfeld R, Berthele A, Hemmer B, Weber MS.

J Neuroinflammation. 2011 Oct 26;8:146. doi: 10.1186/1742-2094-8-146.

5.

A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.

Ray A, Mann MK, Basu S, Dittel BN.

J Neuroimmunol. 2011 Jan;230(1-2):1-9. doi: 10.1016/j.jneuroim.2010.10.037. Epub 2010 Dec 10. Review.

6.

Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity.

Lehmann-Horn K, Kinzel S, Feldmann L, Radelfahr F, Hemmer B, Traffehn S, Bernard CC, Stadelmann C, Brück W, Weber MS.

Ann Clin Transl Neurol. 2014 Jul;1(7):490-6. doi: 10.1002/acn3.71. Epub 2014 Jul 3.

7.

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Weber MS, Prod'homme T, Patarroyo JC, Molnarfi N, Karnezis T, Lehmann-Horn K, Danilenko DM, Eastham-Anderson J, Slavin AJ, Linington C, Bernard CC, Martin F, Zamvil SS.

Ann Neurol. 2010 Sep;68(3):369-83. doi: 10.1002/ana.22081.

8.

Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG.

Ther Adv Neurol Disord. 2017 Jan;10(1):51-66. doi: 10.1177/1756285616666741. Epub 2016 Sep 2. Review.

9.

Anti-CD20 monoclonal antibodies in multiple sclerosis.

Moreno Torres I, García-Merino A.

Expert Rev Neurother. 2017 Apr;17(4):359-371. doi: 10.1080/14737175.2017.1245616. Epub 2016 Oct 21. Review.

PMID:
27718747
10.

Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS.

Eur Neurol. 2015;73(3-4):238-46. doi: 10.1159/000377675. Epub 2015 Mar 25. Review.

11.

Autoreactive CD19+CD20- Plasma Cells Contribute to Disease Severity of Experimental Autoimmune Encephalomyelitis.

Chen D, Ireland SJ, Davis LS, Kong X, Stowe AM, Wang Y, White WI, Herbst R, Monson NL.

J Immunol. 2016 Feb 15;196(4):1541-9. doi: 10.4049/jimmunol.1501376. Epub 2016 Jan 13.

12.

Treatment of multiple sclerosis with anti-CD20 antibodies.

Barun B, Bar-Or A.

Clin Immunol. 2012 Jan;142(1):31-7. doi: 10.1016/j.clim.2011.04.005. Epub 2011 Apr 15. Review.

PMID:
21555250
13.

The role of antibodies in multiple sclerosis.

Weber MS, Hemmer B, Cepok S.

Biochim Biophys Acta. 2011 Feb;1812(2):239-45. doi: 10.1016/j.bbadis.2010.06.009. Epub 2010 Jun 25. Review.

14.

Therapeutic strategies targeting B-cells in multiple sclerosis.

Milo R.

Autoimmun Rev. 2016 Jul;15(7):714-8. doi: 10.1016/j.autrev.2016.03.006. Epub 2016 Mar 9. Review.

PMID:
26970489
15.
16.

Development of anti-CD20 therapy for multiple sclerosis.

Bartok B, Silverman GJ.

Exp Cell Res. 2011 May 15;317(9):1312-8. doi: 10.1016/j.yexcr.2011.04.002. Epub 2011 Apr 12. Review.

17.

Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination.

Rostami A, Ciric B.

J Neurol Sci. 2013 Oct 15;333(1-2):76-87. doi: 10.1016/j.jns.2013.03.002. Epub 2013 Apr 8. Review.

18.

CD16+ gammadelta T cells mediate antibody dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis.

Chen Z, Freedman MS.

Clin Immunol. 2008 Aug;128(2):219-27. doi: 10.1016/j.clim.2008.03.513. Epub 2008 May 22.

PMID:
18501678
19.

B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions.

Claes N, Fraussen J, Stinissen P, Hupperts R, Somers V.

Front Immunol. 2015 Dec 21;6:642. doi: 10.3389/fimmu.2015.00642. eCollection 2015. Review.

20.

Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.

Alwayn IP, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, Treter S, Harper D, Kitamura H, Vitetta ES, Abraham S, Awwad M, White-Scharf ME, Sachs DH, Thall A, Cooper DK.

Xenotransplantation. 2001 Aug;8(3):157-71.

PMID:
11472623

Supplemental Content

Support Center